Jubilant Biosys

In the rapidly evolving landscape of biopharmaceutical research, Antibody-Drug Conjugates (ADCs) are redefining the way targeted therapies are developed and delivered. Combining the precision of monoclonal antibodies with the potent efficacy of cytotoxic drugs, ADCs offer a transformative approach to treating complex diseases such as cancer, central nervous system (CNS) disorders, pain and inflammation, and metabolic disorders. At Jubilant Biosys , our ADC Services are built on cutting-edge science, integrated workflows, and deep domain expertise. From discovery to preclinical development, we empower our partners with tailored ADC solutions that enhance therapeutic potential while minimizing off-target effects.   What Are Antibody-Drug Conjugates (ADCs)? Antibody-Drug Conjugates are sophisticated biopharmaceuticals designed to deliver cytotoxic agents directly to diseased cells. By linking a monoclonal antibody (mAb) specific to a target antigen with a potent payload (dru...

The journey of every drug candidate from laboratory to market depends heavily on how it behaves inside the human body. This behavior is governed by Drug Metabolism and Pharmacokinetics (DMPK) , a critical domain in pharmaceutical research. DMPK studies determine how a drug is absorbed, distributed, metabolized, and excreted (ADME), while also evaluating its potential toxicity and efficacy. As a global leader in drug discovery and development, Jubilant Biosys provides advanced DMPK services that help pharmaceutical and biotech companies make informed decisions early in the pipeline. With a strong scientific foundation and state-of-the-art technology, Jubilant Biosys offers tailored DMPK solutions across multiple therapeutic areas, including Oncology, Central Nervous System (CNS) disorders, Pain and Inflammation, and Metabolic Disorders. This blog explores the role of DMPK in drug discovery and defines Jubilant Biosys’ expertise in these four critical therapeutic areas.   T...